Loading organizations...
Key people at Samlyn Capital.
Samlyn Capital was founded in 2006 by Robert Pohly (Founder).
Samlyn Capital operates as an investment management firm, primarily utilizing a long/short equity strategy. The firm's core approach involves identifying undervalued and overvalued securities, taking long positions in those expected to rise and short positions in those anticipated to fall. This method aims to generate absolute returns across various market conditions through active and disciplined portfolio management.
Robert Pohly founded Samlyn Capital in 2006, leveraging his substantial experience in the financial industry. Prior to establishing the firm, Pohly served as a portfolio manager at Sigma Capital from 2000 to 2006. His insight stemmed from a deep understanding of market inefficiencies and the potential for skilled active management to deliver consistent performance through sophisticated equity analysis.
Samlyn Capital primarily serves institutional investors and high-net-worth individuals who seek specialized equity exposure. The firm’s vision is to consistently deliver strong, risk-adjusted returns by employing rigorous fundamental research and a flexible investment mandate. It remains focused on identifying compelling opportunities and actively managing its portfolio to navigate evolving market landscapes effectively.
Samlyn Capital was founded in 2006 by Robert Pohly (Founder).
Key people at Samlyn Capital.
Samlyn Capital has 1 tracked investment across 1 company. The latest tracked deal is $60.0M Series B in Eliem Therapeutics in May 2021.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| May 1, 2021 | Eliem Therapeutics | $60.0M Series B | Simon Tate, RA Capital Management | 5AM Ventures, Access Biotechnology, Vasudev Bailey, Canaan Partners, Connecticut Innovations, Endeavor Venture Funds, Negev Capital, Nextech Invest, OrbiMed, PsyMed Ventures, Acorn Bioventures, LifeArc |